Sirpiglenastat clinical trials
Also written DRP-104.
How each study uses sirpiglenastat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sirpiglenastat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DRP-104
- 4
Studies by the year they started
4 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · NYU Langone Health (1) · Dracen Pharmaceuticals, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sirpiglenastat.
- Oct 2027DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung CancerPhase 2 · NYU Langone Health
Studies
Open first, then newest update. How each study uses sirpiglenastat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07430202Written as DRP-104
- DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung CancerRecruitingPhase 2NYU Langone HealthNCT07249372Written as DRP-104
- DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)Active, not recruitingPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06027086Written as DRP-104
- Study to Investigate DRP-104 in Adults With Advanced Solid TumorsTerminatedPhase 1/2Dracen Pharmaceuticals, Inc.NCT04471415Written as DRP-104
Codes
What other systems call sirpiglenastat · ClinicalTrials.gg INT015864
- UNII (FDA) 9GGE6A0ZMKSIRPIGLENASTATConfirmed FDA, Wikidata
- Wikidata Q115409266sirpiglenastatConfirmed FDA, Wikidata
- NCI Thesaurus C174038SirpiglenastatOne source FDA
- DrugBank DB17536One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9GGE6A0ZMK | SIRPIGLENASTAT | Confirmed FDA, Wikidata |
| Wikidata | Q115409266 | sirpiglenastat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174038 | Sirpiglenastat | One source FDA |
| DrugBank | DB17536 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.